Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Shares Jump 19 Percent on Strong Q1 Revenue Growth

NEW YORK, May 4 (GenomeWeb News) - Shares in Nanogen were up 19.10 percent, or $.51, at $3.18 in mid-afternoon trading after the company reported a 45-percent jump in first-quarter revenue.

 

Posting its first quarter financials yesterday afternoon, Nanogen said total revenues increased to $3.2 million from $2.2 million year over year. Driving this growth was a surge in licensing fees, which grew to $1.7 million from $152,000 year over year.

 

It was the first quarter to include revenues from Epoch Biosciences, which Nanogen acquired in December 2004. Receipts from product sales, sponsored research, and contracts and grants all fell in the first quarter.

 

Nanogen said R&D spending for the three months ended March 31 increased to $4.9 million from $4.3 million in the year-ago period.

 

Net loss for the quarter jumped to $8.3 million, or $.17 per basic share, from $5.4 million, or $.20 per share, year over year.

 

Nanogen said it had around $12.7 million in cash and equivalents and $27.1 million in short-term investments as of March 31.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.